Back
HFA Premium Access

Careful volume assessment appears to be the critical factor in achieving clinical trial dose of sacubitril/valsartan in the community.

Session: Poster Session 2 - Chronic Heart Failure – Treatment
Topic: Pharmacotherapy
Speaker: Doctor M. Ferre-Vallverdu (Dublin, IE)
Event: Heart Failure 2019

Congress Presentation

Add to my library

Like

About the speaker

Doctor Maria Ferre-Vallverdu

St Vincent's University Hospital, Dublin (Ireland)
0 follower

55 more presentations in this session

Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titration

Speaker: Doctor A. Ntalianis (Athens, GR)

Access
Abstract
Like
Thumbnail

Prescription of sacubitril/valsartan in a real-world population

Speaker: Mr J. AGOSTINHO (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Use of sacubitril-valsartan in heart failure with reduced ejection fraction: real world experience

Speaker: Doctor F. Ferreira (Lisbon, PT)

Access
Abstract
Like
Thumbnail

The dangers of non-heart failure hospitalisation for heart failure patients: frequent medication changes without follow up

Speaker: Ms E. O'Donoghue (Dublin, IE)

Access
Abstract
Like
Thumbnail

Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure.

Speaker: Doctor V. Gomez Leiva (San Salvador, SV)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster Session 2 - Chronic Heart Failure – Treatment

Speakers: Doctor M. Ferre-Vallverdu, Doctor A. Ntalianis, Mr J. AGOSTINHO, Doctor F. Ferreira, Ms E. O'Donoghue...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources